Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics (TAP)
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Participants will:
- Arrive to study visit in a fasted state
- Provide blood, breath, and urine samples prior to intervention
- Complete baseline cognitive assessments
- Self-administer the intervention (time 0), followed by breakfast (time 30 minutes)
- Complete subjective and cognitive assessments throughout treatment visit
- Provide blood, breath, and urine samples throughout treatment visit
- Consume lunch 260 minutes after dosing
- Complete study visit at 360 minutes
- Complete a final study survey
Primary Objective: Characterize the pharmacokinetics of ethanol in participants receiving maintenance Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy (tirzepatide).
Secondary Objectives:
- Determine the effects of GLP-1 RA therapy on alcohol-induced impairment, as measured by
- objective performance
- subjective impairment assessments
- risk perception
Correlative Objectives
- Define the exposure-response relationship between biological alcohol concentrations (breath and blood) and functional impairment to determine if Primary Objective
- Characterize the pharmacokinetics of ethanol in participants receiving maintenance GLP-1 RA therapy (tirzepatide).
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Heather Barkholtz, PhD
- 電話番号:608-890-1967
- メール:hbarkholtz@wisc.edu
研究連絡先のバックアップ
- 名前:Michael Chen, MD
- メール:michael.chen@fammed.wisc.edu
研究場所
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- At least 21 years of age, no older than 55 years of age
- BMI 30-45 kg/m2
- Taking stable dose of prescribed, branded tirzepatide for at least 28 days
- Self-reported regular alcohol consumption
- Good mental health as determined by self-reported responses to the Psychopathology Screener and review by Study Physician as necessary
- Absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the Medical History Screener
- In possession of a valid drivers' license with at least two years of driving experience
- English-speaking (able to provide consent and complete questionnaires)
- Written Informed Consent
Exclusion Criteria:
- AUDIT score of >8 requires Study Physician review
- Use of compounded GLP-1 RA
- History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener, Drug Use Disorders Identification Test, Alcohol Use Disorder Identification Test
- Pregnancy or lactation (pregnancy test, if needed)
- Use of medications that may impact cognitive ability or potentiate alcohol (e.g., mood stabilizers, sedatives)
- Use of medications that are known to significantly delay gastric emptying as determined by Study Physician
- History of pancreatitis, severe gastroparesis, or personal or family history of medullary thyroid or multiple endocrine neoplasia syndrome type 2
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Healthy adults on Tirzepatide
Participants will complete a screening and enrollment visit, one study visit, and a follow-up correspondence over the course of approximately 4 weeks.
|
Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Widmark formula.
A total time of 30 minutes will be given for completion of beverage consumption.
This will be followed by a breakfast.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum Ethanol Concentration (Cmax)
時間枠:prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
Cmax will be determined from visual inspection of the concentration-time plots.
|
prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
|
Time to Maximum Ethanol Concentration (Tmax)
時間枠:prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
Tmax will be determined from visual inspection of the concentration-time plots.
|
prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
|
Ethanol Elimination Rate: Blood samples
時間枠:prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
Data derived from blood samples.
|
prior to dosing (-25 minutes), start of dosing (0 minutes), 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
|
Ethanol Elimination Rate: Breath tests
時間枠:prior to dosing (-25 minutes), 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
Data derived from breath alcohol test.
|
prior to dosing (-25 minutes), 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 240 minutes, 300 minutes, 350 minutes
|
|
Ethanol Elimination Rate: Urine samples
時間枠:prior to dosing (-25 minutes), 60 minutes, 120 minutes, 180 minutes, 240 minutes, 300 minutes
|
Data derived from urine samples.
|
prior to dosing (-25 minutes), 60 minutes, 120 minutes, 180 minutes, 240 minutes, 300 minutes
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biphasic Alcohol Effects Scale (BAES) Score
時間枠:5 minutes, 35 minutes, 65 minutes, 95 minutes, 125 minutes, 185 minutes, 245 minutes, 290 minutes, 340 minutes
|
The BAES has 2 subscales: Stimulant scored from 0-70 and Sedative scored from 0-70.
Higher scores indicate higher stimulant or sedative effects.
|
5 minutes, 35 minutes, 65 minutes, 95 minutes, 125 minutes, 185 minutes, 245 minutes, 290 minutes, 340 minutes
|
|
Risk Perception and Safety Appraisal (RPSA) Score
時間枠:5 minutes, 35 minutes, 65 minutes, 95 minutes, 125 minutes, 185 minutes, 245 minutes, 290 minutes, 340 minutes
|
To quantify cognitive and affective dimensions of risk perception, participants will complete the RPSA questionnaire assessing cognitive and affective risk perception, behavioral risk willingness, metacognitive calibration, and consequence awareness.
This RPSA has been designed by the study team to provide a low burden (12-item), repeatable measure of cognitive, affective, and behavioral dimensions of risk perception, and direct quantification of willingness to engage in safety sensitive behavior.
Scores range from 0-100 where higher scores indicate increased risk perception.
|
5 minutes, 35 minutes, 65 minutes, 95 minutes, 125 minutes, 185 minutes, 245 minutes, 290 minutes, 340 minutes
|
|
Divided Attention Task (DAT)
時間枠:prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes
|
Participants will be asked to complete a computer-based DAT on a laptop in their room.
The DAT requires participants to track a moving stimulus on a computer screen while simultaneously monitoring numbers located in the corners of the screen.
Participants must respond to target numbers as they appear, and the task quantifies the mean distance of the mouse cursor from the center of the target stimulus.
|
prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes
|
|
Digital Symbol Substitution Task (DSST)
時間枠:prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes
|
Participants will be asked to complete a computer-based DSST on a laptop in their room.
The DSST asks participants to recreate patterns of various shapes presented on a computer screen using the keyboard.
The total number of correct patterns are recorded within 90 seconds.
|
prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes
|
|
Paced Serial Addition Task (PSAT)
時間枠:prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes
|
Participants will be asked to complete a computer-based PSAT on a laptop in their room.
The PSAT has participants view a string of single-digit numbers and calculate the sum of the two most recently presented numbers.
The total number of correct trials out of 90 will be recorded.
|
prior to dosing (-20 minutes), 10 minutes, 100 minutes, 220 minutes
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Heather Barkholtz, PhD、UW School of Pharmacy
- 主任研究者:Michael Chen, MD、UW School of Medicine and Public Health
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 2026-1120
- Protocol Version 7/20/26 (その他の識別子:UW Madison)
- Pharmacy | Pharmacy Practice (その他の識別子:UW Madison)
- ICTR TBCR Pilot Award (その他の識別子:UW Madison)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。